Donald Elliott Kohan1, Paola Fioretto2, Kristina Johnsson3, Shamik Parikh4, Agata Ptaszynska5, Lisa Ying6. 1. Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, UT, USA. 2. Department of Medicine, University of Padua, Padua, Italy. 3. Global Medical Affairs, AstraZeneca, Mölndal, Sweden. 4. Global Medical Affairs, AstraZeneca, Wilmington, DE, USA. 5. Bristol-Myers Squibb, Research and Development, Route 206 and Provinceline Road, Princeton, NJ, 08543, USA. agata.ptaszynska@bms.com. 6. Bristol-Myers Squibb, Research and Development, Route 206 and Provinceline Road, Princeton, NJ, 08543, USA.
Abstract
BACKGROUND:Dapagliflozin's antihyperglycemic effects are mediated by inhibition of renal sodium-glucose cotransporter-2; therefore, renal safety of dapagliflozin was assessed. METHODS: Twelve double-blind, placebo-controlled, randomized clinical trials were analyzed up to 24 weeks (N = 4545). Six of the 12 studies included long-term data for up to 102 weeks (N = 3036). Patients with type 2 diabetes with normal or mildly impaired renal function [estimated glomerular filtration rate (eGFR) 60 to <90 mL/min/1.73 m(2)] were treated with dapagliflozin (2.5, 5, or 10 mg/day) or placebo. Renal adverse events (AEs) were assessed. RESULTS: Mean eGFR showed small transient reductions with dapagliflozin at week 1, but returned to near baseline values by week 24 and remained stable to week 102. Mean eGFR changes were not very different for dapagliflozin 2.5, 5 and 10 mg versus placebo at 102 weeks: -0.74, 2.52 and 1.38 versus 1.31 mL/min/1.73 m(2), respectively. Renal AEs were similar in frequency to placebo through 24 weeks (1.4, 1.3, 0.9, and 0.9 %, respectively) and 102 weeks (2.4, 1.8, 1.9 and 1.7 %, respectively). Few were serious (0.2, 0.1, 0 and 0.3 %, respectively, over 102 weeks). The most common renal event was serum creatinine increase. In sub-group analyses in patients ≥65 years of age or those with moderate renal impairment (eGFR 30 to <60 mL/min/1.73 m(2)), renal AEs occurred more frequently with dapagliflozin than placebo. No events of acute tubular necrosis were reported. CONCLUSION: In patients with normal or mildly impaired renal function, dapagliflozin is not associated with increased risk of acute renal toxicity or deterioration of renal function. All trials included in this analysis are registered at ClinicalTrials.gov: NCT00263276, NCT00972244, NCT00528372, NCT00736879, NCT00528879, NCT00855166, NCT00357370, NCT00680745, NCT00683878, NCT00673231, NCT00643851, NCT00859898.
RCT Entities:
BACKGROUND:Dapagliflozin's antihyperglycemic effects are mediated by inhibition of renal sodium-glucose cotransporter-2; therefore, renal safety of dapagliflozin was assessed. METHODS: Twelve double-blind, placebo-controlled, randomized clinical trials were analyzed up to 24 weeks (N = 4545). Six of the 12 studies included long-term data for up to 102 weeks (N = 3036). Patients with type 2 diabetes with normal or mildly impaired renal function [estimated glomerular filtration rate (eGFR) 60 to <90 mL/min/1.73 m(2)] were treated with dapagliflozin (2.5, 5, or 10 mg/day) or placebo. Renal adverse events (AEs) were assessed. RESULTS: Mean eGFR showed small transient reductions with dapagliflozin at week 1, but returned to near baseline values by week 24 and remained stable to week 102. Mean eGFR changes were not very different for dapagliflozin 2.5, 5 and 10 mg versus placebo at 102 weeks: -0.74, 2.52 and 1.38 versus 1.31 mL/min/1.73 m(2), respectively. Renal AEs were similar in frequency to placebo through 24 weeks (1.4, 1.3, 0.9, and 0.9 %, respectively) and 102 weeks (2.4, 1.8, 1.9 and 1.7 %, respectively). Few were serious (0.2, 0.1, 0 and 0.3 %, respectively, over 102 weeks). The most common renal event was serum creatinine increase. In sub-group analyses in patients ≥65 years of age or those with moderate renal impairment (eGFR 30 to <60 mL/min/1.73 m(2)), renal AEs occurred more frequently with dapagliflozin than placebo. No events of acute tubular necrosis were reported. CONCLUSION: In patients with normal or mildly impaired renal function, dapagliflozin is not associated with increased risk of acute renal toxicity or deterioration of renal function. All trials included in this analysis are registered at ClinicalTrials.gov: NCT00263276, NCT00972244, NCT00528372, NCT00736879, NCT00528879, NCT00855166, NCT00357370, NCT00680745, NCT00683878, NCT00673231, NCT00643851, NCT00859898.
Authors: Scott C Thomson; Timo Rieg; Cynthia Miracle; Hadi Mansoury; Jean Whaley; Volker Vallon; Prabhleen Singh Journal: Am J Physiol Regul Integr Comp Physiol Date: 2011-09-21 Impact factor: 3.619
Authors: Volker Vallon; Kenneth A Platt; Robyn Cunard; Jana Schroth; Jean Whaley; Scott C Thomson; Hermann Koepsell; Timo Rieg Journal: J Am Soc Nephrol Date: 2010-07-08 Impact factor: 10.121
Authors: B Komoroski; N Vachharajani; D Boulton; D Kornhauser; M Geraldes; L Li; M Pfister Journal: Clin Pharmacol Ther Date: 2009-01-07 Impact factor: 6.875
Authors: Volker Vallon; Maria Gerasimova; Michael A Rose; Takahiro Masuda; Joseph Satriano; Eric Mayoux; Hermann Koepsell; Scott C Thomson; Timo Rieg Journal: Am J Physiol Renal Physiol Date: 2013-11-13
Authors: K Kaku; S Inoue; O Matsuoka; A Kiyosue; H Azuma; N Hayashi; T Tokudome; A M Langkilde; S Parikh Journal: Diabetes Obes Metab Date: 2013-01-25 Impact factor: 6.577
Authors: Erik J M van Bommel; Marcel H A Muskiet; Lennart Tonneijck; Mark H H Kramer; Max Nieuwdorp; Daniel H van Raalte Journal: Clin J Am Soc Nephrol Date: 2017-03-02 Impact factor: 8.237